Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
Completed
Eisai Inc.
Phase 2
2004-08-01
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose
levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's
Disease who are taking Aricept.
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
Completed
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2
2004-08-01
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose
levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's
Disease who are taking Aricept.
Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)
Completed
Teva Pharmaceutical Industries
Phase 2
2004-08-01
The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose
levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's
Disease who are taking Aricept.
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
Completed
Teva Neuroscience, Inc.
Phase 3
1997-07-01
Study to look at the effectiveness, tolerability and safety of two doses of Study Medication
in Early Parkinson's Disease (PD) Patients who have not been treated with Levodopa.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
